Case Report

Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer

Department of Oncology, 5th Medicial Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China

‡Authors contributed equally

Search for more papers by this author

Jie Li‡

Department of Pathology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China

‡Authors contributed equally

Search for more papers by this author

Qi Xiong‡

https://orcid.org/0000-0002-7782-6498

Department of Oncology, 5th Medicial Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China

‡Authors contributed equally

Search for more papers by this author

Ya Ping Long

https://orcid.org/0000-0002-2706-3656

School of Medicine, Nankai University, 94 Weijin Road, Nankai, Tian Jin, 300071, China

Search for more papers by this author

Bo Yang

Department of Thoracic Surgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China

Search for more papers by this author

Zhou Huan Dong

Department of Pathology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China

Search for more papers by this author

Chao Yang Liang

*Author for correspondence:

E-mail Address: chaoyangliang301@163.com

Department of Thoracic Surgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China

Search for more papers by this author

Bo Yang

**Author for correspondence:

E-mail Address: yangbo@301hospital.com.cn

https://orcid.org/0000-0002-8989-9387

Department of Oncology, 5th Medicial Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China

Search for more papers by this author

Published Online:31 May 2023https://doi.org/10.2217/imt-2022-0302

View article

Abstract

Neoadjuvant therapy and adjuvant therapy for locally advanced non-small-cell lung cancer (NSCLC) with ALK fusion mutation have not been thoroughly studied. Here, a stage IIIB NSCLC patient with EML4-ALK fusion mutation receiving immunotherapy plus chemotherapy as neoadjuvant treatment followed by lobectomy plus lymph node dissection is reported. The patient achieved a pathological complete response according to pathological evaluation. The patient received adjuvant crizotinib for 3 months and achieved a disease-free survival time of 36 months.

Plain language summary

A 50-year-old man was diagnosed with lung cancer. Surgery was not initially an option due to the seriousness of the disease. He received two cycles of treatment and the tumor became obviously smaller. Then, he received an operation. No tumor cells were discovered after detection. The patient had one gene that was not normal. Consequently, he was administered medicine for 3 months. The patient has had good health for at least 36 months.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
MedlineGoogle Scholar
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
MedlineGoogle Scholar
3. Forde PM, Spicer J, Lu S et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386(21), 1973–1985 (2022). • On the basis of this trial, nivolumab in combination with chemotherapy has been approved in the USA as a neoadjuvant treatment for resectable non-small-cell lung cancer (NSCLC).
Medline CASGoogle Scholar
4. Men Y, Wang L, Zhang Y et al. Trends of postoperative radiotherapy for completely resected non-small cell lung cancer in China: a hospital-based multicenter 10-year (2005–2014) retrospective clinical epidemiological study. Front. Oncol. 9, 786 (2019).
MedlineGoogle Scholar
5. Groome PA, Bolejack V, Crowley JJ et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2(8), 694–705 (2007).
MedlineGoogle Scholar
6. Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 388(10048), 1012–1024 (2016).
MedlineGoogle Scholar
7. Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 35(1), 75–91 (2016).
Medline CASGoogle Scholar
8. Blumenthal GM, Bunn PA Jr, Chaft JE et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J. Thorac. Oncol. 13(12), 1818–1831 (2018).
Medline CASGoogle Scholar
9. Hellmann MD, Chaft JE, William WN Jr et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 15(1), e42–e50 (2014).
Medline CASGoogle Scholar
10. Pataer A, Kalhor N, Correa AM et al. Histopathologic response criteria predict /survival of patients with resected lung cancer after neoadjuvant chemotherapy. J. Thorac. Oncol. 7(5), 825–832 (2012).
MedlineGoogle Scholar
11. Pisters KM, Vallieres E, Crowley JJ et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J. Clin. Oncol. 28(11), 1843–1849 (2010).
Medline CASGoogle Scholar
12. Felip E, Rosell R, Maestre JA et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J. Clin. Oncol. 28(19), 3138–3145 (2010).
Medline CASGoogle Scholar
13. Scagliotti GV, Pastorino U, Vansteenkiste JF et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J. Clin. Oncol. 30(2), 172–178 (2012).
Medline CASGoogle Scholar
14. Chaft JE, Dunphy M, Naidoo J et al. Adaptive neoadjuvant chemotherapy guided by (18)F-FDG PET in resectable non-small cell lung cancers: the NEOSCAN trial. J. Thorac. Oncol. 11(4), 537–544 (2016).
MedlineGoogle Scholar
15. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13(1), 25–32 (2012).
Medline CASGoogle Scholar
16. Muthusamy B, Patil PD, Pennell NA. Perioperative systemic therapy for resectable non-small cell lung cancer. J. Natl Compr. Canc. Netw. 20(8), 953–961 (2022).
Medline CASGoogle Scholar
17. Rami-Porta R, Ball D, Crowley J et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 2(7), 593–602 (2007).
MedlineGoogle Scholar
18. Pentheroudakis G. Recent update to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 31(9), 1265–1266 (2020).
Medline CASGoogle Scholar
19. Daly ME, Singh N, Ismaila N et al. Management of stage III non-small-cell lung cancer: ASCO Guideline. J. Clin. Oncol. 40(12), 1356–1384 (2022).
MedlineGoogle Scholar
20. Zhong WZ, Yan HH, Chen KN et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct. Target. Ther. 8(1), 76 (2023). • This was the first randomized phase 2 study to compare neoadjuvant tyrosine kinase inhibitor treatment with chemotherapy for stage IIIA-N2 EGFR-mutated NSCLC patients.
Medline CASGoogle Scholar
21. Camidge DR, Kono SA, Flacco A et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 16(22), 5581–5590 (2010).
Medline CASGoogle Scholar
22. Karachaliou N, Santarpia M, Gonzalez Cao M et al. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. Expert Opin. Investig. Drugs 26(6), 713–722 (2017).
Medline CASGoogle Scholar
23. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27(26), 4247–4253 (2009).
Medline CASGoogle Scholar
24. Koivunen JP, Mermel C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14(13), 4275–4283 (2008).
Medline CASGoogle Scholar
25. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561–566 (2007).
Medline CASGoogle Scholar
26. Zhong WZ, Wang Q, Mao WM et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 19(1), 139–148 (2018).
Medline CASGoogle Scholar
27. Yue D, Xu S, Wang Q et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir. Med. 6(11), 863–873 (2018).
Medline CASGoogle Scholar
28. Shu CA, Gainor JF, Awad MM et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21(6), 786–795 (2020).
Medline CASGoogle Scholar
29. Zhang C, Chen H-F, Yan S et al. Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: a multicenter pooled analysis. NPJ Precis. Oncol. 6(1), 66 (2022). • This study described the inspiring clinical efficacy of neoadjuvant immunotherapy in the largest cohort of patients with resectable NSCLC harboring oncogene mutations.
Medline CASGoogle Scholar
30. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67(2), 138–155 (2017).
MedlineGoogle Scholar
31. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). EUR. J. CANCER. 45(2), 228–247 (2009).
Medline CASGoogle Scholar
32. Ettinger DS, Wood DE, Aisner DL et al. NCCN Guidelines® Insights: Non-small cell lung cancer, version 2.2023. J. Natl. Compr. Canc. Netw. 21(4), 340–350 (2023).
Medline CASGoogle Scholar
33. Garrido P, Rosell R, Massuti B et al. Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clin. Lung Cancer 10(3), 180–186 (2009).
Medline CASGoogle Scholar
34. Goldstraw P, Chansky K, Crowley J et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11(1), 39–51 (2016).
MedlineGoogle Scholar
35. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 359(6382), 1350–1355 (2018).
Medline CASGoogle Scholar
36. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 62, 29–39 (2018).
Medline CASGoogle Scholar
37. Garassino MC, Cho BC, Kim JH et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 19(4), 521–536 (2018).
Medline CASGoogle Scholar
38. Mazieres J, Drilon A, Lusque A et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30(8), 1321–1328 (2019).
Medline CASGoogle Scholar
39. Lee CK, Man J, Lord S et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J. Thorac. Oncol. 12(2), 403–407 (2017).
MedlineGoogle Scholar
40. Socinski M-A, Mok T-S, Nishio M et al. Abstract CT216: IMpower 150 final analysis: efficacy of atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer (NSCLC) across key subgroups. 80, CT216 (2020). • This was the first randomized phase 3 trial of a checkpoint inhibitor in combination with chemotherapy and anti-VEGF therapy to show an improvement in progression-free survival and overall survival in patients with sensitive EGFR mutations.
Google Scholar
41. Rothschild SI, Zippelius A, Eboulet EI et al. SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J. Clin. Oncol. 39(26), 2872–2880 (2021).
Medline CASGoogle Scholar
42. Shen D, Wang J, Wu J et al. Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma. J. Thorac. Dis. 13(3), 1760–1768 (2021).
MedlineGoogle Scholar
43. Provencio M, Nadal E, Insa A et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21(11), 1413–1422 (2020).
Medline CASGoogle Scholar
44. Zhong WZ, Chen KN, Chen C et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J. Clin. Oncol. 37(25), 2235–2245 (2019).
Medline CASGoogle Scholar
45. Jiang SX, Yamashita K, Yamamoto M et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int. J. Cancer 123(11), 2480–2486 (2008).
Medline CASGoogle Scholar
46. Dong ZY, Zhai HR, Hou QY et al. Mixed responses to systemic therapy revealed potential genetic heterogeneity and poor survival in patients with non-small cell lung cancer. Oncologist 22(1), 61–69 (2017).
Medline CASGoogle Scholar
47. Zhang C, Li SL, Nie Q et al. Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement. J. Thorac. Oncol. 14(4), 726–731 (2019).
Medline CASGoogle Scholar
48. Leonetti A, Minari R, Boni L et al. Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO trial. Clin. Lung Cancer 22(5), 473–477 (2021).
Medline CASGoogle Scholar
49. Christensen JG, Zou HY, Arango ME et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6(12 Pt 1), 3314–3322 (2007).
Medline CASGoogle Scholar
50. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371(23), 2167–2177 (2014).
MedlineGoogle Scholar
51. Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 73(18), 2031–2051 (2013).
Medline CASGoogle Scholar
52. Wu YL, Lu S, Lu Y et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J. Thorac. Oncol. 13(10), 1539–1548 (2018).
MedlineGoogle Scholar
53. Camidge DR, Dziadziuszko R, Peters S et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of Alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J. Thorac. Oncol. 14(7), 1233–1243 (2019).
Medline CASGoogle Scholar
54. Solomon BJ, Bauer TM, Ignatius Ou SH et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J. Clin. Oncol. 40(31), 3593–3602 (2022).
Medline CASGoogle Scholar
55. Wu YL, Tsuboi M, He J et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383(18), 1711–1723 (2020).
Medline CASGoogle Scholar
56. Zhang C, Wu YL, Zhong WZ. Rapid postoperative relapse in ALK-positive locally advanced NSCLC patient with complete pathological response to neoadjuvant crizotinib. J. Thorac. Oncol. 14(10), e234–e236 (2019).
MedlineGoogle Scholar
57. Xie XH, Zhan ZJ, Qin YY et al. Case report: neoadjuvant and adjuvant crizotinib targeted therapy in stage IIIA-N2 ALK-positive non-small-cell lung cancer. Front. Oncol. 11, 655856 (2021).
MedlineGoogle Scholar

Vol. 15, No. 11

Metrics

Downloaded 244 times

History

Received 11 December 2022

Accepted 28 April 2023

Published online 31 May 2023

Published in print August 2023

Information

Keywords

Author contributions

B Yang and CY Liang: conceptualization, methodology and supervision; J Li and Q Xiong: data curation and writing: original draft preparation; YP Long: visualization and investigation; ZH Dong: software and validation; Q Song: writing, review and editing.

Financial & competing interests disclosure

This study was supported by the National Natural Science Foundation of China (no. 81902912). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Acknowledgments

The authors acknowledge the invaluable contribution of the study participants, as well as Lin Han Sheng, for providing plain language summary on this case.

Ethical conduct of research

The authors state that they have obtained verbal and written informed consent from the patient for the inclusion of their medical and treatment history in this case report.

PDF download